3 results
The purpose of this study is to investigate how quickly and to what extent different doses of EUapproved Tysabri® are absorbed and eliminated from the body (this is called pharmacokinetics) and how the body responds to different doses of Tysabri (…
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
The objective of the proposed study is to confirm the findings of the dose ranging trial by, primarily, assessing the effect of two doses of CHF6001 on the rate reduction of moderate and severe exacerbations, when added onto maintenance triple…